Pancreatic (PANC-1) tumor-bearing mice were treated with bevacizumab (AvastinÂ®) alone, GL-ONC1 alone, or GL-ONC1 in combination with bevacizumab. Genelux scientists found that Avastin alone led to slow and insignificant delays in tumor growth in comparison to untreated tumors. After injection with GL-ONC1, however, we observed the characteristic pattern resulting in continual regression over time. When viral therapy of GL-ONC1 was given in combination with the injection of bevacizumab during virus treatment, tumor growth inhibition was even greater in comparison to virus-only treatment. A treatment regime combining virotherapy with immunotherapy thus may give better results than each treatment alone and warrants further clinical testing.